Eisai CoESALF 74 EPS without NRI is $0.92 as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $35.73 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 784 Drug Manufacturers companies, Eisai Co ranks worse than 76.15% on this metric.
Eisai Co's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.07.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.92.
During the past 12 months, Eisai Co's average earnings per share (NRI) Growth Rate was -16.50% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -10.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -19.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was -19.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Eisai Co's EPS without NRI or its related term are showing as below:
ESALF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.5 Med: 1.2 Max: 77.9
Current: -10.9
During the past 13 years, Eisai Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 77.90% per year. The lowest was -51.50% per year. And the median was 1.20% per year.
ESALF's 3-Year EPS without NRI Growth Rate is ranked worse than 76.15% of 784
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs ESALF: -10.90
Eisai Co's EPS (Diluted) for the
three
months ended in Mar. 2026 was $-0.07.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.92.
Eisai Co's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.07.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.92.
Eisai Co (OTCPK:ESALF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Eisai Co EPS without NRI Related Terms
Eisai Co EPS without NRI Historical Data
* Premium members only.
The historical data trend for Eisai Co's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Eisai Co's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESALF) has a EPS without NRI of $0.92 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Eisai Co and its competitors. According to the industry distribution chart, Eisai Co ranks #597 out of 784 companies in the Drug Manufacturers industry, placing it in the top 76.1%.
Is Eisai Co's EPS without NRI too high?
Eisai Co's current EPS without NRI is $0.92. The Drug Manufacturers industry median EPS without NRI is 9.70. Eisai Co's value of $0.92 is 90.5% below this industry median. Based on the distribution chart, Eisai Co ranks #597 out of 784 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #597 out of 784 companies for EPS without NRI. This places Eisai Co in the lower half of its industry. The industry median EPS without NRI is 9.70. Eisai Co's value of $0.92 is 90.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current EPS without NRI of $0.92 is 90.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current EPS without NRI is $0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.73, compared to a current price of $25.00 — trading 30% below its estimated fair value. The current EPS without NRI is $0.92 and 90.5% below the Drug Manufacturers industry median of 9.70. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Eisai Co (ESALF), the current EPS without NRI is $0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 30% below its estimated GF Value™ of $35.73.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for ESALF:
EPS without NRI: $0.92
GF Value™: $35.73 vs. price of $25.00 (30% below fair value)
Industry Position: 90.5% below the Drug Manufacturers median (#597 of 784)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
